Supernus Pharmaceuticals Completes Merger with Indivior Pharmaceuticals
Supernus Pharmaceuticals (SUPN) completed its merger with Indivior Pharmaceuticals on November 2, 2026, forming Supernus, Inc. The combined company has an 11-product portfolio and headquarters in Rockville, Maryland. Supernus stockholders received 1.5401 Indivior shares per Supernus share. The company borrowed $650 million to fund a $1 billion dividend to Indivior stockholders.
How this was made
The 30-second read
Why it matters
The merger creates a diversified CNS biopharma with a $1 billion dividend and a $650 million loan, introducing both upside from a broader product portfolio and downside from added leverage.
Market read
Merger completion is a material corporate event that can drive short‑term price action and reshape the CNS therapeutic market.
What to watch
Potential synergies from combined R&D pipelines and cross‑selling opportunities may drive future earnings growth.
Background
The article announces the finalization of the merger between Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV), detailing the ownership split, new leadership, and financing of a special cash dividend.
Ticker impact
Supernus Pharmaceuticals completed its merger with Indivior, forming a new combined company and issuing a $1 billion special cash dividend.
potential short‑term pressure as the market prices integration risk and the new $650 M loan facility.
Merger completion is a material event; the added leverage and dividend may weigh on the stock initially, but the expanded product portfolio offers upside.
Indivior shareholders received shares in the combined company and will receive the $1 billion special cash dividend after the merger.
likely modest upside for former Indivior holders as the dividend is paid, but overall share price may be muted by integration costs.
The cash dividend provides immediate value, while the merger's debt load could temper broader price gains.
Market effects
Creates a larger player in the CNS biopharma space, potentially reshaping competitive dynamics.
Adds to the biotech footprint in the U.S. market, with headquarters in Maryland.
The combined company's expanded portfolio may attract international investors seeking exposure to CNS therapies.
Counterpoint
The added debt and integration risk could outweigh the dividend benefit, leading to a longer‑term price decline.
Key entities
- CompanySupernus Pharmaceuticals
US‑listed biopharma completing merger with Indivior.
- CompanyIndivior Pharmaceuticals
US‑listed biopharma merging into the new Supernus, Inc.
